June 26, 2008 : Barr Pharmaceuticals have announced favorable opinion by U.S. District Court for Delaware in it’s favor pertaining to a Para-IV challenge filed for Mirapex (R) i.e. Pramipexole dihydrochloride, the court have ruled the OB listed patents US 4,886,812 as Invalid on the grounds of nonstatutory double patenting.
Pramipexole (INN, trade names Mirapex and Sifrol) is a medication indicated for treating Parkinson's disease and restless legs syndrome (RLS). It is also sometimes used off-label as a treatment for cluster headache or to counteract the problems with low libido experienced by some users of SSRI antidepressant drugs. Pramipexole has shown robust effects on pilot studies in a placebo-controlled proof of concept study in bipolar disorder[1]. Pramipexole is classified as a non-ergoline dopamine agonist.
Source: http://www.rxtimes.com/?p=1633
http://www.bloomberg.com/
No comments:
Post a Comment